Cabergoline is a synthetic ergoline derivative, primarily used as a dopamine receptor agonist. It is not an endogenous hormone but a pharmaceutical compound synthesized for medical use. Cabergoline belongs to the chemical class of ergot alkaloids and is produced in laboratory settings. It is commonly known under the brand names Dostinex and Cabaser. Researchers have focused on its role in managing conditions related to prolactin secretion.
Cabergoline's primary physiological role is to inhibit the secretion of prolactin from the anterior pituitary gland. This makes it particularly useful in treating disorders such as hyperprolactinemia, which can lead to symptoms like infertility, sexual dysfunction, and galactorrhea. Researchers have also explored its potential in managing Parkinson's disease and other conditions characterized by dopaminergic dysfunction.
The mechanism of action of cabergoline involves its high affinity for dopamine D2 receptors, where it acts as an agonist. This interaction leads to the inhibition of prolactin secretion by the pituitary gland. Researchers have found that this action is mediated through the activation of dopamine pathways, which subsequently suppresses prolactin release.
Pharmacokinetically, cabergoline has a long half-life, allowing for less frequent dosing. It is well absorbed orally, with a bioavailability that is not significantly affected by food. The compound is extensively metabolized in the liver, primarily via hydrolysis of the acylurea bond, and its metabolites are excreted mainly in the urine.
Clinically, cabergoline is used to treat hyperprolactinemia and is approved by various regulatory agencies for this purpose. It is generally well-tolerated, but researchers have noted potential side effects such as nausea and dizziness. In terms of regulatory standing, cabergoline is a prescription medication in many countries, reflecting its controlled use in clinical settings.